J F Gera
Overview
Explore the profile of J F Gera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marderosian M, Sharma A, Funk A, Vartanian R, Masri J, Jo O, et al.
Oncogene
. 2006 May;
25(47):6277-90.
PMID: 16702957
The differential expression of the critical cell cycle control proteins cyclin D1 and c-myc has been shown to result in Akt-dependent hypersensitivity of tumor cells to mTOR inhibitors. We have...
2.
Tucker C, Gera J, Uetz P
Trends Cell Biol
. 2001 Apr;
11(3):102-6.
PMID: 11306254
Large-scale two-hybrid screens have generated a wealth of information describing potential protein--protein interactions. When compiled with data from systematic localizations of proteins, mutant screens and other functional tests, a network...
3.
Gera J, Baker E
Mol Cell Biol
. 1998 Mar;
18(3):1498-505.
PMID: 9488466
The alpha- and beta-tubulin mRNAs of Chlamydomonas reinhardtii exhibit different half-lives under different conditions: when expressed constitutively, they degrade with half-lives of about 1 h, whereas when induced by deflagellation,...
4.
Gera J, Fady C, Gardner A, Jacoby F, Briskin K, Lichtenstein A
J Immunol
. 1993 Oct;
151(7):3746-57.
PMID: 8376804
To test whether DNA injury contributes to TNF-induced cytotoxicity, we attempted to enhance DNA injury by inhibiting its repair and then assessing effects on cytotoxicity. DNA repair, assayed as unscheduled...
5.
Fady C, Gardner A, Gera J, Lichtenstein A
Cancer Immunol Immunother
. 1993 Oct;
37(5):329-36.
PMID: 8104695
Treatment of HER2/neu-overexpressing target cells with interferon gamma (IFN gamma) (200-2000 U/ml for 3 days) markedly enhances their sensitivity to lymphokine-activated killer (LAK) cell lysis. Increased sensitivity is associated with...
6.
Fady C, Gardner A, Gera J, Lichtenstein A
Cancer Immunol Immunother
. 1993 May;
36(5):307-14.
PMID: 8097427
HER2/neu-overexpressing tumor cell lines are relatively resistant to lymphokine-activated killer (LAK) cell cytotoxicity when compared to HER2/neu-nonexpressing lines. HER2/neu+ targets were also resistant to binding by LAK large granular lymphocytes...
7.
Lichtenstein A, Fady C, Gera J, Gardner A, Chazin V, Kelley D, et al.
Cell Immunol
. 1992 Apr;
141(1):219-32.
PMID: 1348216
The mechanism by which HER2/neu overexpressing tumor cells resist NK, LAK, and LDCC cytotoxic lymphocytes was investigated. Resistance was not explained by a delay in kinetics of lysis, concurrent resistance...
8.
Fady C, Gardner A, Gera J, Lichtenstein A
Cancer Res
. 1992 Feb;
52(4):764-9.
PMID: 1346583
Overexpression of the HER2/neu oncogene in ovarian tumor cells is associated with relative resistance to lymphokine-activated killer (LAK) cell cytotoxicity. Treatment with gamma-interferon (IFN-gamma) (200-2000 units/ml) for 3 days markedly...
9.
Gera J, Lichtenstein A
Cell Immunol
. 1991 Nov;
138(1):108-20.
PMID: 1913832
To investigate whether target cell DNA injury participates in cytolysis by human neutrophil defensins (HNP), we analyzed HNP-treated cells for single strand breaks by the alkaline unwinding assay and the...
10.
Lichtenstein A, Gera J, Andrews J, Berenson J, Ware C
J Immunol
. 1991 Mar;
146(6):2052-8.
PMID: 1672341
Four human ovarian and breast tumor lines expressing the HER2/neu oncogene were resistant to the cytotoxic and DNA-degradative activity of TNF. The resistance was not associated with altered TNF receptor...